Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice
Autor: | Joseph S. Marino, Michael J. Turner, Jeanette M. Bennett, Didier Dréau, Nicole L. Stott Bond, Ian Marriott, Susan T Arthur |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Oncology
medicine.medical_specialty QH301-705.5 medicine.medical_treatment Medicine (miscellaneous) Inflammation cachexia General Biochemistry Genetics and Molecular Biology Article Cachexia In vivo Internal medicine medicine Biology (General) skeletal muscle Lung cancer Chemotherapy business.industry Cancer Skeletal muscle medicine.disease Metformin respiratory tract diseases Lewis lung model lung cancer medicine.anatomical_structure medicine.symptom business medicine.drug |
Zdroj: | Biomedicines Volume 9 Issue 11 Biomedicines, Vol 9, Iss 1685, p 1685 (2021) |
ISSN: | 2227-9059 |
Popis: | Non-small-cell lung cancer (NSCLC) makes up 80–85% of lung cancer diagnoses. Lung cancer patients undergo surgical procedures, chemotherapy, and/or radiation. Chemotherapy and radiation can induce deleterious systemic side effects, particularly within skeletal muscle. To determine whether metformin reduces NSCLC tumor burden while maintaining skeletal muscle health, C57BL/6J mice were injected with Lewis lung cancer (LL/2), containing a bioluminescent reporter for in vivo tracking, into the left lung. Control and metformin (250 mg/kg) groups received treatments twice weekly. Skeletal muscle was analyzed for changes in genes and proteins related to inflammation, muscle mass, and metabolism. The LL/2 model effectively mimics lung cancer growth and tumor burden. The in vivo data indicate that metformin as administered was not associated with significant improvement in tumor burden in this immunocompetent NSCLC model. Additionally, metformin was not associated with significant changes in key tumor cell division and inflammation markers, or improved skeletal muscle health. Metformin treatment, while exhibiting anti-neoplastic characteristics in many cancers, appears not to be an appropriate monotherapy for NSCLC tumor growth in vivo. Future studies should pursue co-treatment modalities, with metformin as a potentially supportive drug rather than a monotherapy to mitigate cancer progression. |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...